Zhou C, Shi Z, Ouyang N, Ruan X (2021) Hyperphosphatemia and cardiovascular disease. Front Cell Dev Biol 9:644363. https://doi.org/10.3389/fcell.2021.644363

Article  PubMed  PubMed Central  Google Scholar 

Shaman AM, Kowalski SR (2016) Hyperphosphatemia management in patients with chronic kidney disease. Saudi Pharm J 24:494–505. https://doi.org/10.1016/j.jsps.2015.01.009

Article  PubMed  Google Scholar 

Dube P, DeRiso A, Patel M et al (2021) Vascular calcification in chronic kidney disease: diversity in the vessel wall. Biomedicines 9:404. https://doi.org/10.3390/biomedicines9040404

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goyal R, Jialal I (2024) Hyperphosphatemia. StatPearls. StatPearls Publishing, Treasure Island

Google Scholar 

Vikrant S, Parashar A (2016) Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: a study from a tertiary care hospital in India. Indian J Endocrinol Metab 20:460–467. https://doi.org/10.4103/2230-8210.183457

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rabbani SA, Sathvik SB, Rao PG et al (2017) hyperphosphatemia in end stage renal disease: prevalence and patients characteristics of multiethnic population of United Arab Emirates. Int J Pharm Pharm Sci 9:283. https://doi.org/10.22159/ijpps.2017v9i12.22425

Article  CAS  Google Scholar 

Kalantar-Zadeh K, Forfang D, Bakris G et al (2023) Managing phosphate burden in patients receiving dialysis: beyond phosphate binders and diet. Kidney360 4:1650–1656. https://doi.org/10.34067/KID.0000000000000262

Article  PubMed  PubMed Central  Google Scholar 

Cernaro V, Longhitano E, Calabrese V et al (2023) Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure. Expert Opin Pharmacother 24:1737–1746. https://doi.org/10.1080/14656566.2023.2243817

Article  CAS  PubMed  Google Scholar 

Cernaro V, Longhitano E, Casuscelli C et al (2024) Hyperphosphatemia in chronic kidney disease: the search for new treatment paradigms and the role of tenapanor. Int J Nephrol Renovasc Dis 17:151–161. https://doi.org/10.2147/IJNRD.S385826

Article  PubMed  PubMed Central  Google Scholar 

Robison R, Cooney D, Low MB, Desai N (2016) Sevelamer carbonate and lanthanum usage evaluation and cost considerations at a veteran’s affairs medical center. Hosp Pharm 51:312–319. https://doi.org/10.1310/hpj5104-312

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scaria PT, Gangadhar R, Pisharody R (2009) Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease. Indian J Pharmacol 41:187–191. https://doi.org/10.4103/0253-7613.56074

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eckardt K-U, Kasiske BL (2009) Foreword. Kidney Int 76:S1–S2. https://doi.org/10.1038/ki.2009.188

Article  Google Scholar 

Zhang Q, Li M, Lu Y et al (2010) Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 115:c259–c267. https://doi.org/10.1159/000313484

Article  CAS  PubMed  Google Scholar 

Finn WF (2006) Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. CN 65:191–202. https://doi.org/10.5414/CNP65191

Article  CAS  Google Scholar 

Spencer AG, Labonte ED, Rosenbaum DP et al (2014) Intestinal inhibition of the Na+ /H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. https://doi.org/10.1126/scitranslmed.3007790

Article  PubMed  PubMed Central  Google Scholar 

King AJ, Siegel M, He Y et al (2018) Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med 10:eaam6474. https://doi.org/10.1126/scitranslmed.aam6474

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin T, Al-Makki A, Shepler B (2022) Tenapanor: a new treatment option for hyperphosphatemia in end stage kidney disease. J Pharm Pharm Sci 25:77–83. https://doi.org/10.18433/jpps32284

Article  CAS  PubMed  Google Scholar 

Luo H, Feng J, Zhang Y et al (2023) Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Apher Dial 27:839–847. https://doi.org/10.1111/1744-9987.14028

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https://doi.org/10.1136/bmj.n71

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions 1st ed. Wiley

Book  Google Scholar 

Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https://doi.org/10.1136/bmj.l4898

Article  PubMed  PubMed Central  Google Scholar 

Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712–716. https://doi.org/10.1046/j.1445-2197.2003.02748.x

Article  PubMed  Google Scholar 

StataCorp (2023) Stata statistical software

RevMan. https://training.cochrane.org/online-learning/core-software/revman. Accessed 14 Sep 2023

PlotDigitizer. In: PlotDigitizer. https://plotdigitizer.com. Accessed 28 Apr 2024

Cochrane handbook for systematic reviews of interventions. https://training.cochrane.org/handbook. Accessed 5 Jul 2024

Higgins JPT (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557

Article  PubMed  PubMed Central  Google Scholar 

Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634. https://doi.org/10.1136/bmj.315.7109.629

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Egger M (2001) Funnel plots for detecting bias in meta-analysis. J Clin Epidemiol 54:1046–1055. https://doi.org/10.1016/S0895-4356(01)00377-8

Article  CAS  PubMed  Google Scholar 

Block GA, Rosenbaum DP, Leonsson-Zachrisson M et al (2016) Effect of tenapanor on interdialytic weight gain in patients on hemodialysis. CJASN 11:1597–1605. https://doi.org/10.2215/CJN.09050815

Article  CAS  PubMed  PubMed Central  Google Scholar 

Block GA, Rosenbaum DP, Leonsson-Zachrisson M et al (2017) Effect of tenapanor on serum phosphate in patients receiving hemodialysis. JASN 28:1933–1942. https://doi.org/10.1681/ASN.2016080855

Article  CAS  PubMed  PubMed Central  Google Scholar 

Block GA, Rosenbaum DP, Yan A, Chertow GM (2019) Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. JASN 30:641–652. https://doi.org/10.1681/ASN.2018080832

Article  CAS  PubMed  PubMed Central  Google Scholar 

Block GA, Bleyer AJ, Silva AL et al (2021) Safety and efficacy of tenapanor for long-term serum phosphate control in maintenance dialysis: a 52-week randomized phase 3 trial (PHREEDOM). Kidney360 2:1600–1610. https://doi.org/10.34067/KID.0002002021